# Bill Meury

> Bill Meury is the chief executive officer and a board member of Incyte, based in Wilmington, Delaware. An economics graduate of the University of Maryland, he built his career at Forest Laboratories and Allergan, became a partner at Hildred Capital Management, and later led Karuna Therapeutics and Anthos Therapeutics through acquisitions before joining Incyte in June 2025.

- **Role:** Chief Executive Officer at Incyte
- **Organizations:** Incyte, Hildred Capital Management, Anthos Therapeutics (former), Karuna Therapeutics (former), Allergan (former), Actavis (former), Forest Laboratories (former), MCI Communications (former), Reznick, Fedder & Silverman (former), The Jed Foundation (board member)
- **Education:** Bachelor of Arts in Economics, University of Maryland
- **Known for:** Led Karuna Therapeutics during its transition toward an integrated research and commercial organization and through its acquisition by Bristol Myers Squibb., Led Anthos Therapeutics through its April 2025 acquisition by Novartis., Oversaw an Allergan commercial business with about fifty products, $16 billion in revenue and approximately 8,000 employees.

## Career timeline

- **Before 1993** — Worked in public accounting at Reznick, Fedder & Silverman and financial reporting at MCI Communications.
- **1993** — Joined Forest Laboratories.
- **2014-07** — Moved to executive commercial leadership at Actavis following its acquisition of Forest.
- **2015-03** — Became President, Branded Pharma at Allergan.
- **2016-05** — Appointed Chief Commercial Officer at Allergan.
- **2020-05** — Became a partner at Hildred Capital Management; served through December 2022.
- **2023-01** — Became President and CEO of Karuna Therapeutics on January 3.
- **2024-03** — Karuna acquisition by Bristol Myers Squibb completed March 18.
- **2024-04** — Appointed CEO and board member of Anthos Therapeutics.
- **2025-04** — Novartis completed its acquisition of Anthos on April 3.
- **2025-06** — Joined Incyte as President, CEO and board member on June 26.
- **2026-03** — Remained CEO as Pablo Cagnoni became President of Incyte.

## Achievements

- Led Karuna Therapeutics during its transition toward an integrated research and commercial organization and through its acquisition by Bristol Myers Squibb.
- Led Anthos Therapeutics through its April 2025 acquisition by Novartis.
- Oversaw an Allergan commercial business with about fifty products, $16 billion in revenue and approximately 8,000 employees.
- Appointed CEO and a director of Incyte by unanimous board decision in June 2025.

## Latest updates

- **2026-10** — Discussed growth and expansion plans including Switzerland in an October 5 Le Temps interview.
- **2026-04** — Announced Suketu (Suky) Upadhyay as CFO, effective May 4, with responsibilities including capital allocation and financial planning.
- **2026-03** — Announced expanded executive responsibilities and integration of U.S. commercial teams.

## Links

- Website: https://incyte.com
- LinkedIn: https://www.linkedin.com/in/billmeuryincyte

---

Profile page: https://yespress.io/bill-meury
Published by YesPress — https://yespress.io
Last updated: 2026-10-21